Thomas Q McClelland

Long-term outcomes of prophylactic cardioprotection in early-stage breast cancer patients on non-anthracycline anti-HER2 therapy

Anti-HER2 therapy has improved survival in HER2-positive breast cancer patients for decades but is associated with well-established cardiotoxicity. Our prior randomized controlled trial PROTECT HER2 found no short-term benefit of prophylactic beta-blocker cardio protection (CPT)...